Wellmune wgp Maintained Physical Health and Reduced ‘Down Time’ During 90-Day Study

In a cold season study with 40 healthy subjects, Wellmune wgp reduced the incidence of fever and eliminated the need to miss work or school due to cold-like symptoms. The double-blinded, placebo-controlled study included subjects, aged 18-65, who were treated daily with either 500mg of Wellmune wgp or a placebo for 90 days. Cold/flu symptoms were evaluated by medical staff within 24 hours of onset.

In contrast with the placebo group, the Wellmune wgp group reported an increase in general health markers, including physical energy and emotional well-being, as measured by a clinically validated health survey questionnaire (SF-36v-2).

While there were no significant differences in the incidence of symptomatic respiratory infections among the study groups, the duration and severity of symptoms were alleviated in subjects receiving Wellmune WGP.

In the study results, the Wellmune WGP group reported:

- No missed work or school due to colds, compared with 1.38 days of work/school missed for the placebo group. (p = 0.026)
- No incidence of fever, compared with 3.50 incidence in the placebo group. (p = 0.042)
- An increase in quality of life, including physical energy and emotional well-being, as measured by a clinically validated health survey questionnaire (SF-36v-2). (p = 0.042)
- No adverse events were detected and no safety concerns were present.

### Medically-verified Symptoms and Study Outcomes

<table>
<thead>
<tr>
<th>Variable</th>
<th>Wellmune</th>
<th>Placebo</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of Fever</td>
<td>0.00</td>
<td>3.5 ± 3.42</td>
<td>0.042</td>
</tr>
<tr>
<td>Number of missed days of work/school</td>
<td>0.00</td>
<td>1.38 ± 1.25</td>
<td>0.026</td>
</tr>
</tbody>
</table>